MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas

Ovarian cancer is a silent disease with a poor prognosis that urgently requires new therapeutic strategies. In low-grade ovarian tumours, mutations in the MAP3K BRAF gene constitutively activate the downstream kinase MEK. Here we demonstrate that an additional MAP3K, MAP3K8 (TPL-2/COT), accumulates...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nat Commun
Prif Awduron: Gruosso, Tina, Garnier, Camille, Abelanet, Sophie, Kieffer, Yann, Lemesre, Vincent, Bellanger, Dorine, Bieche, Ivan, Marangoni, Elisabetta, Sastre-Garau, Xavier, Mieulet, Virginie, Mechta-Grigoriou, Fatima
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Pub. Group 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4633961/
https://ncbi.nlm.nih.gov/pubmed/26456302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms9583
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg